Kornimate/medical-research-clean huggingface dataset:
non-invasive pulsed radiofrequency for the treatment of neuropathic pain

Conditions: Pain, Nerve

Summary: the purpose of this study is to examine non-invasive pulsed radiofrequency (niprf) and the effect it has on chronic neuropathic pain. chronic neuropathic pain after peripheral nerve injury most often occurs in the context of post-traumatic or post-surgical pain. it is often treated with nerve blocks, prescription medication, physical therapy, neuromodulation, and surgery. the study team will be examining the efficacy of niprf and determining if it would be an appropriate treatment for chronic neuropathic pain after peripheral nerve injury.the stimpod used in the present study is fda approved and will be used for on label purposes.


Eligibility criteria:
inclusion criteria: * -adults aged 18 or older with clinically diagnosed chronic neuropathic pain after peripheral injury defined as persistent or recurrent neuropathic pain caused by a peripheral nerve lesion, history of a plausible nerve trauma, pain onset in temporal relation to the trauma, and pain distribution within the innervation territory of a peripheral nerve (or nerves). negative and positive sensory symptoms or signs must be compatible with the innervation territory of the affected nerve. can be posttraumatic, post-surgical, nerve compression, nerve ischemia with or without loss of motor function * positive response (at least 50% pain relief) to diagnostic nerve block at the suspected site of cnp-pi. * continued pain despite conservative therapy for a minimum of 12 weeks * stable dosage of analgesic medications for at least 30 days, and willingness to refrain from trialing new analgesic medications for three weeks after randomization * worst pain intensity of ≥5/10 on the numeric rating scale (nrs) of pain (0-10) at the cnp-pi site at enrollment * english-speaking * ability and willingness to complete online and phone assessments exclusion criteria: * conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status) * cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome * painful polyneuropathy (e.g., metabolic, autoimmune, familial, infectious disease, environmental toxins, treatment with neurotoxic drug) * chronic central neuropathic pain (e.g., spinal cord injury, brain injury, multiple sclerosis) * peripheral vascular disease * diabetic neuropathy * other active implantable devices (e.g., implantable cardioverter defibrillator, spinal cord stimulator, dorsal root ganglion stimulator, sacral nerve stimulator, deep brain stimulator, intrathecal pump) * pregnancy, breastfeeding, or planning to conceive * systemic infection or local infection at the anticipated niprf treatment sites * interventional procedure and/or surgery to treat cnp-pi in the last 30 days (subjects should be enrolled 30 days after last procedure, for prior ablative treatment must be enrolled at least 3 months after last procedure) * epilepsy * metal implants within the target treatment area of the niprf.
cefixime versus benzathine penicillin g in treatment of early syphilis

Conditions: Syphilis

Summary: this study evaluates the efficacy (non-inferiority) and safety of a new antibiotic treatment (cefixime), which has been previously used for single dose therapy of gonorrhoea in many years , in the treatment of early syphilis. participants will be randomized to one of two study arms and will receive either expirimental regimen (cefixime) or the current standard antibiotic regimen (benzathine penicillin g). new treatment alternatives for syphilis could ensure that people are appropriately treated during periods or in settings of benzathine penicillin g stock out, penicillin allergy, or other intolerance to penicillin injection. this study may also identify an oral regimen for settings in which injections are not feasible.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. non-pregnant, non breastfeeding 3. able to provide informed consent 4. clinically or laboratory-confirmed primary, secondary or early latent syphilis with a positive rapid treponemal test and an rpr/vdrl titer equal to or greater than 1:8 5. non-cephalosporin allergic 6. non-penicillin allergic 7. agree to be occasionally called by study staff to be reminded to take study drug 8. willing to attend follow-up visits exclusion criteria: 1. under 18 years of age 2. pregnancy, breastfeeding 3. prior history of syphilis in last two years 4. allergy or contraindication to penicillin or cephalosporins (including allergy to cefixime) 5. systemic antibiotic therapy in last two weeks 6. previous enrollment in the study 7. presenting a situation or condition that would not allow reliable study follow up (for example: frequent travel, alcohol abuse or substance misuse)

Keywords: syphilis treatment cefixime
use of local analgesia with epinephrine during total hip arthroplasty (tha)

Conditions: Arthroplasty, Replacement, Hip

Summary: the aim is to determine if the use of infiltration with an adrenalin solution in the operative field of total hip arthroplasty (tha), allays a significant reduction of the cumulated volume of bleeding (pre and post operative) without increasing the per and post operative risks. at the same time, the effect on the post operational pains is evaluated.

this prospective randomized study compares a population receiving a local anaesthetic (ropivacaine, adrenalin and physiological serum) in the operative field to a population undergoing a standard protocol. the cumulated volume of bleeding per and post operative are recorded and complete blood count (cbc).

Eligibility criteria:
inclusion criteria: * primary total hip arthroplasty * age between 50 and 85 exclusion criteria: * fracture of the femoral neck * patients with contraindications for local anaesthesia

Keywords: arthroplasty, hip blood losses pain local analgesia epinephrine primary total hip arthroplasty
a combined aerobic and resistance training program for adults with psychotic disorders

Conditions: Psychosis

Summary: the study is a feasibility study of a combined high intensity aerobic and strenght exercise program for persons with psychotic disorders. the feasibility of the protocol will be investigated, in addition to the participants subjective experience with the participation.

the aim of this study is to investigate the feasibility of a 16 week physical exercise intervention combining strenght and aerobic training in group for patients with psychotic disorders. in addition, the feasibility of the test protocol and participants subjective experience with the intervention will be investigated. research shows positive effects of physical exercise for patients with psychotic disorders regarding maximal aerob training, maximal muscle strength, physical, cognitive and social functioning, and symptom levels. effects and the degree of feasibility of physical exercise for patients with psychotic disorders are amplified by regarding their preferences and needs, and if they experience support and guidance during the intervention. earlier studies have focused mostly on either strength og endurance training, or combined interventions of moderate intensity. we now want to investigate the feasibility of an invidually adjusted combined program of high intensity. after the intervention, participants will be interviewed about their experience with participating.

Eligibility criteria:
participants with psychotic disorder: inclusion criteria: * signed informed consent * diagnosed with psychotic disorder * physically able to participate in physical exercise * is a patient at solli dps * motivated for participating in physical exercise exclusion criteria: * physical conditions precluding the participant from the physical testing/training * mental state that hinders participation, such as ongoing suicidality, substance abuse or brain organic disorder participants with psychiatric disorder, but no psychotic disorder: inclusion criteria: * signed informed consent * diagnosed with psychiatric disorder, but not a psychotic disorder * physically able to participate in physical exercise * is a patient at solli dps * motivated for participating in physical exercise exclusion criteria: * physical conditions precluding the participant from the physical testing/training * mental state that hinders participation, such as ongoing suicidality, substance abuse or brain organic disorder
comparing the effects of pilates and mckenzie in power looms workers having nonspecific chronic low back pain

Conditions: Nonspecific Chronic Low Back Pain; Pain; Disability Physical

Summary: to check the effects of mckenzie intervention \& pilates intervention on power looms workers having nonspecific chronic low back pain

the purpose of this study is to check and compare the effects of mckenzie back extension exercise and pilates pelvic tilt exercise on power looms workers having nonspecific chronic low back pain. to check the effects of these interventions on pain, disability, and anterior pelvic tilt angle. in this study pain intensity of the subjects will be noted via a numeric pain rating scale. pain will be measured at baseline, after 2 weeks and 4 weeks of intervention. in this study disability of the patients will be measured via quebec back pain disability scale. disability will be measured at baseline, after 2 weeks and 4 weeks of intervention. in this study, a goniometer will be used to measure the anterior pelvic tilt angle. anterior pelvic tilt angle will be measured at baseline, after 2 weeks and 4 weeks of intervention.

Eligibility criteria:
inclusion criteria: * age of the participants between 35-45 years. * only male workers diagnosed with nonspecific chronic low back pain. * power looms workers; operator of power looms, working 12 hours per day. * low back pain for more than three months. * power looms workers with pain intensity on nprs ranges from mild to moderate. * anterior pelvic tilt angle more than normal 13º±4.9º, anteriorly tilt to 18º to 25º. exclusion criteria: * serious spinal pathology like tumors. * any inflammatory diseases. * history of spinal surgery. * neurological disorder. * pain due to any systemic diseases.

Keywords: pilates pelvic tilt exercise & mckenzie back exercise
validation of a preclinical model based on patient-derived organoids for the study of the gut-joint axis in spondyloarthritis

Conditions: Spondyloarthritis; Inflammatory Bowel Diseases

Summary: this project aims to develop and validate a model of human organoids derived from patients with spondyloarthritis, focusing on synovial and intestinal tissues as targets of the gut-joint axis. the tissue marker profile of patient-derived organoids studied by gene expression, immunohistochemistry, and cytokine production profile will be compared with that of controls in order to test for the presence of specific biomarkers.


Eligibility criteria:
inclusion criteria: * more than 18 years of age; * ability to understand and sign an informed consent form; * clinical indication for intestinal and/or synovial biopsy; * only for spa patients group: meeting asas classification criteria. exclusion criteria: * actively treated cancer; * severe comorbidities that, in the investigator\&#39;s opinion, may affect the quality of samples for planned experimental applications; * only for patients undergoing ileal-colic biopsy: history of colorectal cancer disease, celiac disease; * only for patients undergoing a synovial biopsy: septic arthritis.
treatment of the hutchinson-gilford progeria syndrome with a combination of pravastatin and zoledronic acid

Conditions: Hutchinson-Gilford Progeria Syndrome

Summary: we suggest treating the hutchinson-gilford progeria syndrome by two molecules (zoledronic acid and pravastatin).the therapeutic approach which we propose has for objectives to reduce, to prevent or to delay the gravest infringements of the disease, to prolong the life of the children, and in a more general way, aim at improving their living conditions.


Eligibility criteria:
inclusion criteria: * molecularly characterised patients with a known mutation of their lmna gene leading to the production of a farnesylated prelamin a, whether truncated or not * patients must be able to travel and consult in marseille, france for necessary explorations planned at the inclusion step, then following the protocol flow * chart for zoledronic acid injections and follow-up visits * patient older than 3 years * patients affiliated or beneficiary of a legal medical insurance * adult patients certifying they have been properly informed about the protocol, and they signed a written consent form. children and/or disabled patients whose parents/legal tutor have been informed and have signed a written consent form exclusion criteria: * known hypersensitivity to pravastatin or zoledronic acid * seric transaminase levels higher than 3 times of normal value * cpk level higher than 5 times of normal value * creatininemia higher than 0.5mg/dl or 44mm, or creatinin clearance lower than 70ml/min/1.73m3 * presence of dental troubles, or recent dental trouble * maxillary osteonecrosis or bone nakedness antecedent * congenital galacosemia, glucose or galactose maladsorption syndrome, lactase deficiency * every other pathology thought to be incompatible with proposed treatment by the investigator * under treatment that can interfere with pravastatin and/or zoledronate metabolisms
efficacy and safety of rivastigmine capsules in patients with probable vascular dementia

Conditions: Vascular Dementia

Summary: the goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.


Eligibility criteria:
inclusion criteria: * between the ages of 50 and 85 years old * have contact with a responsible caregiver 3 or more days per week * be male or a female who is surgically sterilized or one year post menopausal exclusion criteria: * current diagnosis of severe or unstable cardiovascular or other diseases * current diagnosis of active, uncontrolled seizure disorder, parkinson's disease or alzheimer's disease

Keywords: dementia,vascular,rivastigmine,stroke,memory loss
plasma copeptin levels in children with diabetic ketoacidosis

Conditions: Diabetic Ketoacidosis Children

Summary: children with diabetic ketoacidosis risk neurological complications such as cerebral edema with high morbidity. to prevent cerebral edema, it is essential to control correction of hypovolemia, hyperglycemia and natremia. markers usually used in management of diabetic ketoacidosis don't always permit an optimal care. plasma copeptin levels reflect vasopressin secretion which is high in diabetic ketoacidosis. therefore, monitoring of plasma copeptin levels could be of interest in children with diabetic ketoacidosis and risk of sévère neurological complications.

biological risk factors for severe complications in diabetic ketoacidosis are described (high blood glucose level, metabolic acidosis, high blood urea nitrogen, hypernatremia) but their dosage and monitoring are not sufficient to distinguish high risks situations. several studies suggest that vasopressin secretion is increased in diabetic ketoacidosis. this high level could be important in occurrence of cerebral edema. monitoring of vasopressin levels could then have an interest in patients at risk of severe complications but reliability of copeptin dosage depend of collection conditions and its packaging. these conditions are difficult to ensure and copeptin dosage, which represent vasopressin secretion, is easier to perform. copeptin dosage could then be a new biological marker, more accurate and specific, for an optimal management of diabetic ketoacidosis. this type of study has never been carried out neither in children nor in adults.

Eligibility criteria:
inclusion criteria: * children between 6 months and 16 years * diagnosis of diabetes mellitus type 1 (cardinal syndrome, blood glucose level \> 7 mmol/l in the fasted state or \> 11 mmol/l not in fasted state, no signs for another type of diabetes mellitus) * children who need an exclusive intravenous rehydration for 36 hours * written informed consent of legal representative and of the child if possible * beneficiary of state social insurance exclusion criteria: * child under the age of 6 months or older than 16 years * non exclusive intravenous réhydration for at least 36 hours * child moved from another institution and for whom an intravenous rehydration or insulin therapy have already begun * non type 1 diabetes mellitus * non affiliation to state social insurance
reliability of function tests for people with back pain.

Conditions: Low Back Pain; Adult

Summary: back pain is often accompanied by changes in function. the performance of individuals with their backs on their wills may become more functional. it is believed that the test will present good to excellent reliability in individuals with chronic back pain. from this, it can be used in the clinic to verify the functional capacity of these individuals.

this study will be performed to verify the reliability of the functional tests for individuals with back pain. a study in which individuals with back pain will be assessed on the first day and after the interval of seven days. they should perform the 6-minute walk test and answer some questionnaires such as the roland morris - disability questionnaire, the ipaq - physical activity level questionnaire and numeric rating scale, after the tests will be performed timed 10-meter walk test and 30 second sit to stand test. to avoid a random error, a minimum sample size of 30 participants is required. for statistical analysis, shapiro-wilk test will be used for data normalization and the reliability between measurements will be calculated through do intraclass correlation coefficients, standard error of measurement and minimal detectable change. there were no studies in the literature and recorded in the clinical trials that evaluated the reliability of these tests for individuals with chronic low back pain.

Eligibility criteria:
inclusion criteria: * both sexes aged 20 to 65 years and low back pain for more than 3 months. exclusion criteria: * acute pain of back pain that disables the performance of the tests. * pregnancy. * neoplasms. * known heart, lung or metabolic diseases. * hypotension (bp \ 140 x 90 mmhg), medicated or not. * fall or faint in the previous two months. * have not undergone any spinal surgery. * have not had neuromuscular impairment in the last three months and who need help to follow the instructions.

Keywords: musculoskeletal disease stress test reproducibility gait speed
combination therapy for cancer related fatigue in patients with metastatic cancers

Conditions: Metastatic Cancers; Fatigue

Summary: to find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational interventions or the placebo alone.

primary objectives: 1. to determine if the combination therapy of pi with olp (combination therapy group) is superior to pi alone group in the treatment of cancer-related fatigue (crf) as measured by the functional assessment of chronic illness therapy-fatigue (facit-f) scale. we hypothesize that the combination of olp+pi in these patients will result in a greater reduction of crf compared to pi alone. secondary objectives: 1. to determine if combination therapy group is superior to pi only group for the treatment of crf at 3 months and 6 months after treatment. we hypothesize that the combination of olp+pi in these patients will result in a greater reduction of crf after 3 months and 6 months after treatment 3. to determine the effects of combination therapy on fatigue-related quality-of-life, mood, sleep-wake activity, cognitive measures, and inflammation. we will assess measures including quality of life (functional assessment of cancer therapy - general, fact- g), multidimensional fatigue (multidimensional fatigue symptom inventory, mfsi-sf), sleep disturbance (promis-sleep), anxiety (hospital anxiety and depression scale - hads), depressed mood (hads), cognitive function (symbol digit modality test, sdmt), sleep/wake time activity (actigraphy), and inflammation (c-reactive protein levels). we hypothesize that combination therapy will result in improvements in crf-related quality of life, mood, sleep-wake activity, and cognitive measures.

Eligibility criteria:
inclusion criteria: 1. be advanced cancer patients (incurable metastatic), having fatigue with severity of 4/10, on a 0-10 scale (edmonton symptom assessment scale) for at least 2 weeks. 2. have no clinical evidence of cognitive failure as evidenced by treating clinician assessment at screening (memorial delirium assessment scale of less than 13/30). 3. be aged 18 years or older. 4. be willing to complete in-person or with research staff, and able to complete psychoeducational intervention either in person or virtually within texas. 5. have a hemoglobin level of ≥10 g/dl within 2 weeks of enrollment. 6. be able to understand the description of the study and sign a written informed consent. 7. have a ecog performance status score of 0 to 2; and 8. be seen at an outpatient clinic at md anderson cancer center's (mda) main campus or its houston area locations (hals) exclusion criteria: 1. have a major contraindication to placebo (e.g., allergy or hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physician. 2. be unable to complete the baseline assessment forms or to understand the recommendations for participation in the study. 3. be pregnant or become pregnant while on study.
newborn screening for severe combined immunodeficiency (scid) in a high-risk population

Conditions: Severe Combined Immunodeficiency; T Cell Lymphocytopenia

Summary: the goal of the proposed research is to establish the validity of a newborn screening method for severe combined immunodeficiency (scid). the assay to be used is developed on the basis of pcr quantification of t-cell receptor excision circles (trecs) that is absent in scid patients, thus correlating with the disease

to show that early diagnosis of scid with a trec screening assay can warrant timely treatment of the disease and avoid life-threatening infections on patients. babies with scid are unable to fight infections. they become severely ill in their first months of life and do not survive unless their immune systems can be restored. scid can be treated by bone marrow transplant if recognized early. the newborn screening test to be employed in this study is designed to diagnose scid before infections occur. by conducting a pilot testing program in a high-risk population on the navajo indian reservation, where one in 2,000 infants is born with scid, we hope to confirm the benefits of newborn screening for early diagnosis of scid

Eligibility criteria:
inclusion criteria: * birth in a study hospital on the navajo reservation exclusion criteria: * none

Keywords: trec t cell primary immunodeficiency pid navajo scid